Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 4,915 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,915 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $20.01, for a total transaction of $98,349.15. Following the transaction, the insider now directly owns 159,357 shares in the company, valued at approximately $3,188,733.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, May 13th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.33, for a total transaction of $30,861.99.
• On Monday, April 29th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.56, for a total transaction of $31,437.68.
• On Monday, April 15th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $13.95, for a total transaction of $34,916.85.
• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.17, for a total transaction of $965,130.57.

Hims & Hers Health Trading Down 2.1 %

Shares of NYSE:HIMS opened at $15.83 on Friday. The company’s 50-day moving average price is $14.11 and its 200 day moving average price is $11.04. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $20.11.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. Hims & Hers Health’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.05) EPS. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HIMS shares. Truist Financial increased their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. Guggenheim raised their price target on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. TheStreet raised shares of Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Finally, Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.69.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $638,000. Strategic Wealth Partners Ltd. acquired a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $839,000. Bayesian Capital Management LP acquired a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $1,770,000. SVB Wealth LLC acquired a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $421,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Hims & Hers Health by 239.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 168,427 shares of the company’s stock worth $2,606,000 after purchasing an additional 118,848 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.